UPLOAD Filing
Ensysce Biosciences, Inc.
Date: April 13, 2026 · CIK: 0001716947 · Accession: 0000000000-26-003700
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-294939
Letter
Re: Ensysce Biosciences, Inc. Registration Statement on Form S-3 Filed April 9, 2026 File No. 333-294939 Dear Lynn Kirkpatrick:
April 13, 2026
Lynn Kirkpatrick President, Chief Executive Officer and Director Ensysce Biosciences, Inc. 7946 Ivanhoe Avenue, Suite 201 La Jolla, CA 92037
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Gregory J. Rubis, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> April 13, 2026 Lynn Kirkpatrick President, Chief Executive Officer and Director Ensysce Biosciences, Inc. 7946 Ivanhoe Avenue, Suite 201 La Jolla, CA 92037 Re: Ensysce Biosciences, Inc. Registration Statement on Form S-3 Filed April 9, 2026 File No. 333-294939 Dear Lynn Kirkpatrick: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Gregory J. Rubis, Esq. </TEXT> </DOCUMENT>